Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Abstract

This work distinguishes del-<i>NOTCH</i> ^mut as a potential predictor to favorable ICI response in NSCLC, highlighting the importance of genomic profiling in immunotherapy. More importantly, our results unravel a possibility of personalized combination immunotherapy as adding NOTCH inhibitor to ICI regimen in NSCLC, for the optimization of ICI treatment in clinical practice.